Trials / Completed
CompletedNCT02365506
Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome
A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the effect of oral eleclazine (formerly GS-6615) on corrected QT (QTc) interval in participants with long QT2 syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eleclazine | Tablets administered orally in a single dose |
| DRUG | Placebo | Placebo to match tablets administered orally in a single dose |
Timeline
- Start date
- 2015-07-20
- Primary completion
- 2016-05-13
- Completion
- 2016-06-13
- First posted
- 2015-02-19
- Last updated
- 2020-12-30
- Results posted
- 2020-12-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02365506. Inclusion in this directory is not an endorsement.